Aquestive Therapeutics Inc (AQST) Institutional Holdings & 13F Data (Q2 2026)

AQST ranks #3145 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

AQST is a top-conviction position for Bratton Capital Management, L.P. — at 100.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Two Sigma Investments, LP has added to its AQST position for two straight quarters, increasing it by $2.9M to reach $5.3M today.

Morgan Stanley has trimmed its AQST position for two straight quarters, cutting it by $8.6M while still holding $2.7M.

AQST is up 2.7% today, and institutions have been net buyers of $29.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AQST reported a net loss of $78.2M over the trailing twelve months.

• Not yet profitable — net loss of $78.2M over the trailing twelve months
• Revenue grew 22.6% year over year
• Net income declined year over year, from -$65.0M to -$78.2M
• Operating cash flow was negative, using $52.4M in cash
• Current ratio of 3.14x — enough short-term assets to cover short-term liabilities